Family practitioners and sexually transmitted diseases

MARC STEBEN, MD, CCFP

The family practitioner's role has traditionally been to maintain health with periodic examinations and to restore health in times of illness and injuries. Today, family practitioners are expected to play a more proactive role by assessing unexpressed patient needs. This new approach focuses on global knowledge of the patient, including lifestyle and workplace history. When assessing sexually transmitted diseases (STDs) in particular, it is important for the family practitioner to recognize the association of morality issues and to counsel without being judgemental. Primary prevention of STDs is aimed at reducing or eliminating risks before exposure occurs, and includes counselling on safe sex, condom use, substance abuse, needle/syringe use, and consideration of hepatitis B immunization and universal screening of pregnant women for hepatitis B surface antigen. Secondary prevention refers to the recognition and elimination (if possible) of an STD after exposure and includes early disease detection, adequate STD treatments, screening, human immunodeficiency virus testing with pre- and post test counselling, epidemiological treatment of patient contacts, and hepatitis B prophylaxis by passive or active immunization. Tertiary prevention is aimed at limiting disease progression or reversing damage, but such measures are usually quite expensive and of limited value. Assessment of risks for hepatitis B virus infection should include lifestyle indices such as sexual preference, sexual expression, number of partners and alcohol/drug consumption. Prostitutes, street youth and sexually abused individuals should be considered at high risk for hepatitis B virus infection. Counselling about hepatitis B virus infection involves risk evaluation, patient education, evaluation of immune status to hepatitis B virus and discussions about vaccine needs and availability.

Key Words: Counselling. Family practitioners. Prevention. Sexually transmitted diseases

Le médecin de famille et les maladies transmissibles sexuellement

RESUME: Le rôle traditionnel du médecin de famille consistait à maintenir la santé de ses clients par des examens périodiques, et à assurer leur rétablissement en cas de maladies ou de transmattineres. Mais aujourd'hui, le médecin de famille doit assumer un rôle plus actif et évaluer les besoins que certains patients n'expriment pas ou ne reconnaissent pas. Cette nouvelle approche est axée sur la connaissance globale du patient - modes de vie et activités professionnelles y compris. Quand il examine un patient à la recherche de maladies transmissibles sexuellement (MTS) en particulier, il est important que le médecin de famille reconnaisse qu'il entre dans le domaine des questions morales: il se doit de conseiller sans juger. La...
W E A R E C U R R E N T L Y I N T H E M I D S T O F A W O R L D­ W A I D E E P I D E M I C O F S E X U A L L Y T R A N S M I T T E D D I S­ EASES (STDs). N o t h a v i n g b e e n a b l e t o r e s o l v e t h e gonorrea and chlamydia problems, we are enter­ ing the era of viral STDs. F o r m o s t v i r a l STDs there is chronicity, no curative treatment and the threat of oncogenicity. F a m i l y p r a c t i t i o n e r s h a v e b e e n v i r a l p l a y e r s i n m a j o r b r e a k t h r o u g h s i n p r e v e n t i v e m e d i c i n e. F o r e x a m p l e, w i t h o u t h e l p f r o m f a m i l y p r a c t i t i o n e r s, s u c h s i g n i f i c a n t d e c l i n e s i n t h e p r e v a l e n c e s o f t u b e r c u l o s i s, c e r v i c a l c a n c e r a n d c a r d i o v a s c u l a r d i s e a s e c o u l d n o t h a v e b e e n a c h i e v e d. S i m i l a r l y , f a m i l y p r a c t i t i o n e r s s h o u l d b e r e g a r d e d a s k e y m e m b e r s o f t h e h e a l t h p r o f e s­ s i o n a l t e a m i n t h e f i g h t a g a i n s t S T D s .

F a m i l y p r a c t i t i o n e r s a r e i n v o l v e d i n m a n y a r e a s o f t h e C a n a d i a n h e a l t h c a r e s y s t e m , f r o m c l i n i c a l a n d h o s p i t a l s e t t i n g s t o , m o r e r e c e n t l y , t h e w o r k­ p l a c e a n d s c h o o l . T h e i r r o l e s h a v e c e n t r e d o n m a i n t a i n i n g h e a l t h b y t i m e l y p e r i o d i c e x a m i n a­ t i o n s a n d s c r e e n i n g f o r d i s e a s e b e f o r e c o m p l i c a­ t i o n s , a n d o n r e s t o r i n g h e a l t h i n t i m e s o f i l l n e s s a n d i n j u r i e s . F a m i l y p r a c t i t i o n e r s ’ r o l e s t o d a y a r e c h a n g i n g , h o w e v e r , a s t h e y a r e e x p e c t e d t o b e m o r e p r o a c t i v e , e s p e c i a l l y i n t h e f i e l d o f S T D s . T h e n e w a p p r o a c h i s c e n t r e d o n a c q u i r i n g g l o b a l k n o w­ l e d g e o f t h e p a t i e n t , w h i c h i n c l u d e s l i f e s t y l e a n d w o r k p l a c e i s s u e s . I n a d d i t i o n , f a m i l y p r a c t i t i o n e r s m u s t a t t e m p t t o a s s e s s t h e u n e x p r e s s e d n e e d s o f p a t i e n t s (1).

S T D s r e m a i n a p u z z l e f o r m a n y g e n e r a l p r a c t i t i o n e r s . G e n e r a l p r a c t i t i o n e r s h a v e r a n k e d d i a g­ n o s i n g S T D s f i f t h o n a l i s t o f 2 4 p r i m a r y c a r e a n d h e a l t h c a r e p r o b l e m s , a c c o r d i n g t o a s t u d y i n Q u e e b e c b y L e c l e r e e t a l (2). S i n c e S T D s a r e l i n k e d t o m o r t a l i t y i s s u e s a n d t a b o o s , i t i s o f t h e u t m o s t i m p o r t a n c e t h a t f a m i l y p r a c t i t i o n e r s r e c o n i z e t h e i m p l i c a t i o n s o f t h e i r o w n p e r s o n a l v a l u e s c l a s h i n g w i t h t h o s e o f s o m e S T D p a t i e n t s . F a m i l y p r a c t i t i o n e r s s h o u l d a t t e m p t t o e l i m i n a t e o r r e d u c e p a t i e n t r i s k s r e l a t e d t o s e x a n d d r u g s w i t h e d u c a t i o n a n d c o u n s e l l i n g , n o t w i t h j u d g e m e n t a l r e m a r k s .

P R I M A R Y P R E V E N T I O N

P r i m a r y p r e v e n t i o n i s a c h i e v e d b y r e d u c i n g o r e l i m i n a t i n g e x p o s u r e o r b y h i g h t e n i n g d e f e n c e m e c h a n i s m s a g a i n s t t h e a g e n t o f d i s e a s e . F a m i l y p r a c t i t i o n e r s a r e r e s p o n s i b l e f o r “ s a f e s e x ” c o u n s e l l ­ i n g a n d s h o u l d k n o w t h e a p p r o p r i a t e c o l o n i a l s e x u a l e x p r e s s i o n s . T h e y s h o u l d t e a c h p a t i e n t s h o w t o r e c o g n i z e t h e r i s k s o f S T D s i n s e x u a l p a r t n e r s a n d d i s c u s s h o w t o n e t h i c a l p r o t e c t i o n . S a f e s e x c o u n s e l l i n g s h o u l d i n c l u d e a t h o r o u g h q u e s t i o n n a i r e a b o u t s e x u a l p r e f e r e n c e s , s e x u a l e x p r e s s i o n s , n u m b e r s o f p a r t n e r s a n d , w h e n n e c e s s a r y o r a p p r o p r i a t e , c o m m e r c i a l s e x a n d s e x u a l a b u s e (3). S t r e e t y o u t h a n d p e o p l e w i t h o u t k n o w n a d d r e s s e s s h o u l d b e i d e n t i f i e d a s t h e y a r e a p p a r e n t l y v u l n e r a b l e g r o u p s . U s e o f c o n d o m s s h o u l d b e d i s c u s s e d w i t h r e s p e c t t o t h e b e s t t y p e (e g , l a t e x) o r b a n d t o b u y , h o w t o p r e v e n t b r e a k­ a g e o r , i f t h e p a t i e n t d o e s n o t u s e t h e m , w h y n o t . S u b s t a n c e a b u s e s h o u l d b e d i s c u s s e d a s i t t e n d s t o d e c r e a s e p r e v e n t i v e b e h a v i o u r . F u r t h e r m o r e , r e f e r r a l f o r d e t o x i f i c a t i o n a n d o r e d u c a t i o n a b o u t a c c e s s t o c l e a n i n j e c t i o n m a t e r i a l d r a m a t i c a l l y d e c r e a s e s h u m a n i m m u n o d e f i c i e n c y v i r u s (H I V) s e r o c o n v e r s i o n i n i n f r a m e s c e n t r e d u g u s e r s (4).

H e p a t i t i s B v a c c i n a t i o n i s v e r y i m p o r t a n t s i n c e i t a c h i e v e s o v e r 9 5 % p r o t e c t i o n i n h e p a t i t i s B v i r u s-ex p o s e d s u b j e c t s (5). O v e r h a l f o f a c u t e h e p a t i t i s B v i r u s i n f e c t i o n s a r e s e x u a l l y t r a n s m i t­ t e d (a b o u t 2 5 % h e r o s e x u a l l y , 3 3 % h o m o­ s e x u a l l y ) . V a c c i n a t i o n o f s e x u a l l y a c t i v e p e r s o n s i s
persons is associated with a beneficial cost/benefit ratio, even at today's cost [6]. Universal screening of all patients in a primary care setting for hepatitis B surface antigen and active and passive vaccination of their offspring (recommended by the National Advisory Committee on Immunization) are also of great public health benefit. Difficulties with implementing such a strategy such as in vitro fertilization for infertility arising from chlamydial salpingitis is quite expensive and of limited efficacy; fewer than 10% of in vitro fertilization cycles produce a live birth [9]; it could thus cost more than $60,000 per live birth (based on actualized costs from American studies [10]). Zidovudine (AZT), on the other hand, reduces the incidence of HIV infection but costs from $2000 to $8000 per year of treatment and is in no way curative. Acyclovir can prevent resurgence of herpes simplex virus infection but can cost from $30 per episode to $1200 a year for suppressive therapy. Interferon alpha-2b has been shown to stop hepatitis B virus replication in hepatic cells of chronic carriers and can cost over $15,000 per patient treated. Compared to primary prevention, tertiary prevention is not very cost effective: treatment of one carrier of hepatitis B virus with interferon alpha-2b would cost the same as administering hepatitis B virus vaccinations to a group of 120 people.

SECONDARY PREVENTION
Secondary prevention involves elimination of the agent of disease after exposure but before complications. Early disease recognition by both patient and physician is very important since many STDs manifest clinically for only brief periods before symptoms disappear despite persistence of the disease agent. Adequate STD treatment is also important since exposure to inadequate dosages may increase the risk of resistance to antimicrobials and increase subclinical disease in patients. Consequently, these patients may continue spreading the inadequately treated STDs to former or new sexual partners in the false belief that they have been cured. It is also advisable to screen patients in whom infection is suspected and to treat 'epidemiologically' contacts of proven index cases, even without confirmation test results [3]. Hepatitis B virus post exposure prophylaxis for sexual, nonsexual and parenteral contact is feasible with passive and/or active vaccination [8]. Post exposure prophylaxis is more effective if given soon after contact. Appropriate management of contacts should be outlined in a policy for which adequate education would be required.

TERTIARY PREVENTION
Tertiary prevention is aimed at limiting disease progression or reversing damage due to disease. A strategy such as in vitro fertilization for infertility arises from chlamydial salpingitis is quite expensive and of limited efficacy; fewer than 10% of in vitro fertilization cycles produce a live birth [9]; it could thus cost more than $60,000 per live birth (based on actualized costs from American studies [10]). Zidovudine (AZT), on the other hand, reduces the evolution of HIV infection but costs from $2000 to $8000 per year of treatment and is in no way curative. Acyclovir can prevent resurgence of herpes simplex virus infection but can cost from $30 per episode to $1200 a year for suppressive therapy. Interferon alpha-2b has been shown to stop hepatitis B virus replication in hepatic cells of chronic carriers and can cost over $15,000 per patient treated. Compared to primary prevention, tertiary prevention is not very cost effective: treatment of one carrier of hepatitis B virus with interferon alpha-2b would cost the same as administering hepatitis B virus vaccinations to a group of 120 people.

COUNSELLING ABOUT HEPATITIS B VIRUS
Identification of STD risk is frequently not considered in a medical history. Hepatitis B virus risk can be determined with good workplace and STD risks assessment and social indices reconnoissance. Since the general population and the average patient know little about hepatitis B virus compared to HIV or syphilis, education about hepatitis B virus infection is crucial [11]. Educational material about hepatitis B virus is available through the Canadian Liver Foundation, various provincial health agencies and drug companies. Patient consent for hepatitis B virus vaccination must be based on prior discussions with a family practitioner on the benefits, potential side effects and limitations of the vaccine. In addition, pre-vaccination evaluation of immune status by appropriate serological testing may be warranted for individuals suspected of exposure. Patients with limited financial resources, for whom accessibility might be a concern, should be informed of the availability of public health vaccination programs.

Since the target populations and costs for hepatitis B virus immunization would be similar to those for HIV immunization, hepatitis B virus immunization represents a unique public health opportunity for in-field practice before an HIV vaccine becomes available [8].

In conclusion, family practitioners are obligated to take a proactive role in the treatment and prevention of STDs. Procrastination by family practitioners and public health authorities in implementing hepatitis B virus immunization programs will prove costly to the health care system and patients.

REFERENCES
1. Blondeau F. L'anamnese centrée sur le malade. Can Fam Physician 1990:36:1509-13.
2. Leclere H, Beauleau MD, Bordage G, et al. Why are clinical problems difficult? General practitioners' opinions concerning 14 clinical problems. Can Med Assoc J. 1990;143:1305-15.
3. 1989 Sexually transmitted diseases. Treatment

Can J Infect Dis Vol 2 Suppl A August 1991 29A
4. Gruer L. Opening session. The First National Workshop on HIV Infection and Injection Drug Use: Strategies for Prevention, Montreal, 1990.

5. Szmuness W, et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (HEPATAX B): A final report. Hepatology 1981:1:577.

6. Cates W. Viral STD: What can we do besides educate? STD-88 National Conference ‘Partnership for Prevention’, YEAR:23-6.

7. Lague J. Les travailleurs de la santé. In: Le sida, Un Nouveau Défi Médical, Montréal: Association des médecins de langue française du Canada, 1990:239.

8. Canadian Immunization Guide. Can Med Assoc J 1989;141:227-8.

9. Medical Research International. The fertility society special interest group: In vitro fertilization. Embryo transfer in the United States: 1985 and 1986 results from national IVF/ET registry. Fertil Steril 1988;49:212.

10. Clinca S, Cooper MS. Analysis of the costs of infertility treatment. Am J Public Health 1986;72:1018-9.

11. Steben M, Pelletier J, Fluet M, et al. Attitudes and perceptions about certain aspects of STD. International Society for STD Research Annual Meeting, Atlanta, Georgia, 1987.
